Resources

Discover the science behind and promising potential of Bexion’s emerging cancer therapies

RESET ALL FILTERS

Press Releases

view all

Bexion Pharmaceuticals, Inc. Announces Completion of Enrollment

Read Press Release

Bexion Pharmaceuticals, Inc. to Participate in the Jefferies London Healthcare Conference

Read Press Release

Bexion Pharmaceuticals, Inc. Awarded Grant from The Michael J. Fox Foundation

Read Press Release

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at SITC

Read Press Release

Articles

view all

CRC Stats

Interdisciplinary Care of Children with Diffuse Midline Glioma

Contemporary Survival Endpoints an International DIPG Registry Trial

Diffuse High-Grade Gliomas with H3 K27M Cutations Carry a Dismal Prognosis Independent of Tumor Location

Treatment of mCRC-ASCO Guidelines

Efficacy and Quality of Life for FOLFOX/bevacizumab – Supplemental Appendix

Abstracts and Fact Sheets

View All

Ped SNO BXQ-350

SITC 2024 Abstract

2024 Analytical Platform AACR Abstract

AACR 2022 CIPN

AACR 2022 MOA

AACR 2024 MOA

Posters

View All

2025 ASCO GI Trial in Progress mCRC

2022 CIMT Solid Tumor Poster

2022 EANO CIPN Poster

2022 ISPNO DIPG Poster

2022 ISPNO Ependymoma Patients Poster

2022 WIS Copenhagen Solid Tumor Poster

Clinical Trials

view all

BXQ-350 AB Ph1 Ped Article

View Clinical Trial

BXQ-350 AA Manuscript Supplemental Appendix

View Clinical Trial

BXQ-350 AA Manuscript

View Clinical Trial